TY - JOUR
T1 - Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure
AU - Quintas-Cardama, Alfonso
AU - Kantarjian, Hagop
AU - Jones, Dan
AU - Nicaise, Claude
AU - O'Brien, Susan
AU - Giles, Francis
AU - Talpaz, Moshe
AU - Cortes, Jorge
PY - 2007/1/15
Y1 - 2007/1/15
N2 - Developing strategies to counteract imatinib resistance constitutes a challenge in chronic myelogenous leukemia (CML). Therapy with the tyrosine kinase inhibitors nilotinib (AMN107) and dasatinib (BMS-354825) has produced high rates of hematologic and cytogenetic response. Src kinase activation has been linked to Bcr-Abl-mediated leukemogenesis and CML progression. In addition to binding Abl kinase with less stringent conformational requirements than imatinib, dasatinib is a potent Src kinase inhibitor. In the current study, we report on 23 patients with CML (19 of them in accelerated or blastic phases) treated with dasatinib after treatment failure with both imatinib and nilotinib. More than half (13; 57%) of 23 patients responded to dasatinib: 10 (43%) had a complete hematologic response (CHR), including 7 (30%) who had a cytogenetic response (2 complete, 4 partial, and 1 minor). These results suggest that dasatinib may be active in some patients after failure with both imatinib and nilotinib.
AB - Developing strategies to counteract imatinib resistance constitutes a challenge in chronic myelogenous leukemia (CML). Therapy with the tyrosine kinase inhibitors nilotinib (AMN107) and dasatinib (BMS-354825) has produced high rates of hematologic and cytogenetic response. Src kinase activation has been linked to Bcr-Abl-mediated leukemogenesis and CML progression. In addition to binding Abl kinase with less stringent conformational requirements than imatinib, dasatinib is a potent Src kinase inhibitor. In the current study, we report on 23 patients with CML (19 of them in accelerated or blastic phases) treated with dasatinib after treatment failure with both imatinib and nilotinib. More than half (13; 57%) of 23 patients responded to dasatinib: 10 (43%) had a complete hematologic response (CHR), including 7 (30%) who had a cytogenetic response (2 complete, 4 partial, and 1 minor). These results suggest that dasatinib may be active in some patients after failure with both imatinib and nilotinib.
UR - http://www.scopus.com/inward/record.url?scp=33846200681&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846200681&partnerID=8YFLogxK
U2 - 10.1182/blood-2006-07-035493
DO - 10.1182/blood-2006-07-035493
M3 - Article
C2 - 16990591
AN - SCOPUS:33846200681
SN - 0006-4971
VL - 109
SP - 497
EP - 499
JO - Blood
JF - Blood
IS - 2
ER -